American Regent, Inc v. Bpi Labs, LLC

Court

District Court, M.D. Florida (M.D. Fla.)
Official Court Website →

Docket number

8:25-cv-01470

Cause

35:271 Patent Infringement
35 U.S.C. § 271 — Patent infringement

Nature of suit

835 Patent - Abbreviated New Drug Applications (ANDA)
Hatch-Waxman patent disputes over a generic-drug (ANDA) application.

Jurisdiction

Federal Question

Jury demand

None

Date filed

06/06/2025

Parties

• plaintiff · American Regent, Inc · 12 cases
• defendant · Bpi Labs, LLC · 5 cases

Part of a Larger Litigation Pattern

This is one of 6 Patent - ANDA cases in our index naming BPI LABS, LLC — a possible mass-tort or coordinated-litigation cluster.

About Patent - ANDA Lawsuits

ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.

Frequently Asked Questions

What is American Regent, Inc v. Bpi Labs, LLC?

American Regent, Inc v. Bpi Labs, LLC is a federal patent - anda lawsuit filed on 06/06/2025 in the District Court, M.D. Florida. The case is currently open in the federal court system. ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.

What type of case is this?

It is classified as “Patent - ANDA” under the federal nature-of-suit system. ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.

What court is the case in?

The case is in the District Court, M.D. Florida, docket number 8:25-cv-01470.

When was the case filed?

American Regent, Inc v. Bpi Labs, LLC was filed on 06/06/2025. The case is currently open.

What law is the case brought under?

The docket lists the cause as 35 U.S.C. § 271 — Patent infringement.